Article Sidebar
Main Article Content
Abstract
Background: Malignant pleural effusion (MPE) is a clinical problem in which fluid accumulates in the pleural cavity. This condition is generally caused by malignancy. Pleurodesis is a medical procedure in the form of fusion of the visceral and parietal pleura in order to prevent the recurrence of pleural effusion. Pleurodesis has the risk of causing chronic inflammation, which will trigger excessive attachment between the visceral and parietal pleura. Of course, an intervention is needed to reduce the risk of inflammation, one of which is by using a pleurodesis agent, which has an anti-inflammatory effect. This study aimed to compare the efficacy of povidone-iodine compared to bleomycin as a pleurodesis agent in malignant pleural effusion patients at Dr. Hasan Sadikin General Hospital, Bandung, Indonesia.
Methods: Prospective cohort study, where as many as 46 research subjects participated in this study and were grouped into groups that received povidone-iodine and bleomycin. The success of pleurodesis agents was assessed by the production of WSD. Data analysis was carried out using SPSS univariate and bivariate.
Results: The results of the study showed that there was no statistical difference between the 10% povidone-iodine agent and the bleomycin agent, where p>0.05. However, in the 10% povidone-iodine group, the success rate was 100%, while in the bleomycin group, the success rate was 82.6%.
Conclusion: There was no significant difference in the efficacy of povidone-iodine as a pleurodesis agent compared to bleomycin in patients with malignant pleural effusion at Dr. Hasan Sadikin General Hospital, Bandung, Indonesia.
Keywords
Article Details
As our aim is to disseminate original research article, hence the publishing right is a necessary one. The publishing right is needed in order to reach the agreement between the author and publisher. As the journal is fully open access, the authors will sign an exclusive license agreement.
The authors have the right to:
- Share their article in the same ways permitted to third parties under the relevant user license.
- Retain copyright, patent, trademark and other intellectual property rights including research data.
- Proper attribution and credit for the published work.
For the open access article, the publisher is granted to the following right.
- The non-exclusive right to publish the article and grant right to others.
- For the published article, the publisher applied for the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
